The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go -related gene (hERG) potassium channels

Autor: Hung-Fat Tse, Gui-Rong Li, J Guo, XH Zhang, Chu-Pak Lau, W Li, S Zhang, Qiang Tang, Hai-Ying Sun, ZQ Li
Rok vydání: 2008
Předmět:
Zdroj: British Journal of Pharmacology. 155:365-373
ISSN: 0007-1188
Popis: Background and purpose: Ketanserin, a selective 5-HT receptor antagonist, prolongs the QT interval of ECG in patients. The purpose of the present study was to determine whether ketanserin would block human cardiac ether-a-go-go-related gene (hERG) potassium channels. Experimental approach: Whole-cell patch voltage-clamp technique was used to record membrane currents in HEK 293 cells expressing wild type or mutant hERG channel genes. Key results: Ketanserin blocked hERG current (IhERG) in a concentration-dependent manner (IC50=0.11 μM). The drug showed an open channel blocking property, the block increasing significantly at depolarizing voltages between +10 to +60 mV. Voltage-dependence for inactivation of hERG channels was negatively shifted by 0.3 μM ketanserin. A 2.8 fold attenuation of inhibition by elevation of external K+ concentration (from 5.0 to 20 mM) was observed, whereas the inactivation-deficient mutants S620T and S631A had the IC50s of 0.84±0.2 and 1.7±0.4 μM (7.6 and 15.4 fold attenuation of block). In addition, the hERG mutants in pore helix and S6 also significantly reduced the channel block (2–59 fold) by ketanserin. Conclusions and implications: These results suggest that ketanserin binds to and blocks the open hERG channels in the pore helix and the S6 domain; channel inactivation is also involved in the blockade of hERG channels. Blockade of hERG channels most likely contributes to the prolongation of QT intervals in ECG observed clinically at therapeutic concentrations of ketanserin. British Journal of Pharmacology (2008) 155, 365–373; doi:10.1038/bjp.2008.261; published online 23 June 2008
Databáze: OpenAIRE